Figure 1.
The network between ILC2s and cells of the innate and adaptive immune system and a schematic of investigative and approved biologic therapies. Biologics target IgE, IL-5 and its receptor, IL-4 receptor, and alarmins such as TSLP and IL-33, leading to the suppression of asthma exacerbation and improved asthma control. Tiotropium suppresses basophil-derived IL-4 production, and R848, a toll-like receptor7 (TLR7) agonist, induces macrophage-derived IL-27 production. These pathways also indirectly induce the suppression of ILC2-mediated airway eosinophilic inflammation. ILC2, type 2 innate lymphoid cell; M3R, muscarinic M3 receptor.